169 related articles for article (PubMed ID: 23554861)
21. Gene silencing of TGF-β1 enhances antitumor immunity induced with a dendritic cell vaccine by reducing tumor-associated regulatory T cells.
Conroy H; Galvin KC; Higgins SC; Mills KH
Cancer Immunol Immunother; 2012 Mar; 61(3):425-31. PubMed ID: 22193988
[TBL] [Abstract][Full Text] [Related]
22. IL-28A is a key regulator of T-cell-mediated liver injury via the T-box transcription factor T-bet.
Siebler J; Wirtz S; Weigmann B; Atreya I; Schmitt E; Kreft A; Galle PR; Neurath MF
Gastroenterology; 2007 Jan; 132(1):358-71. PubMed ID: 17241885
[TBL] [Abstract][Full Text] [Related]
23. IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells.
He D; Li H; Yusuf N; Elmets CA; Li J; Mountz JD; Xu H
J Immunol; 2010 Mar; 184(5):2281-8. PubMed ID: 20118280
[TBL] [Abstract][Full Text] [Related]
24. Endogenous IL-33 exerts CD8
Xia Y; Ohno T; Nishii N; Bhingare A; Tachinami H; Kashima Y; Nagai S; Saito H; Nakae S; Azuma M
Biochem Biophys Res Commun; 2019 Oct; 518(2):331-336. PubMed ID: 31421832
[TBL] [Abstract][Full Text] [Related]
25. Forced co-expression of IL-21 and IL-7 in whole-cell cancer vaccines promotes antitumor immunity.
Gu YZ; Fan CW; Lu R; Shao B; Sang YX; Huang QR; Li X; Meng WT; Mo XM; Wei YQ
Sci Rep; 2016 Aug; 6():32351. PubMed ID: 27571893
[TBL] [Abstract][Full Text] [Related]
26. Bone marrow transplantation generates T cell-dependent control of myeloma in mice.
Vuckovic S; Minnie SA; Smith D; Gartlan KH; Watkins TS; Markey KA; Mukhopadhyay P; Guillerey C; Kuns RD; Locke KR; Pritchard AL; Johansson PA; Varelias A; Zhang P; Huntington ND; Waddell N; Chesi M; Miles JJ; Smyth MJ; Hill GR
J Clin Invest; 2019 Jan; 129(1):106-121. PubMed ID: 30300141
[TBL] [Abstract][Full Text] [Related]
27. Local IL-21 promotes the therapeutic activity of effector T cells by decreasing regulatory T cells within the tumor microenvironment.
Kim-Schulze S; Kim HS; Fan Q; Kim DW; Kaufman HL
Mol Ther; 2009 Feb; 17(2):380-8. PubMed ID: 19034262
[TBL] [Abstract][Full Text] [Related]
28. Treatment-enhanced CD4+Foxp3+ glucocorticoid-induced TNF receptor family related high regulatory tumor-infiltrating T cells limit the effectiveness of cytokine-based immunotherapy.
Berhanu A; Huang J; Watkins SC; Okada H; Storkus WJ
J Immunol; 2007 Mar; 178(6):3400-8. PubMed ID: 17339434
[TBL] [Abstract][Full Text] [Related]
29. Increased tumor-infiltrating CD45RA
Mao FY; Kong H; Zhao YL; Peng LS; Chen W; Zhang JY; Cheng P; Wang TT; Lv YP; Teng YS; Fu XL; Liu YG; Wu XL; Hao CJ; You N; Luo P; Yu PW; Zou QM; Guo G; Zhuang Y
Cell Death Dis; 2017 Aug; 8(8):e3002. PubMed ID: 28817117
[TBL] [Abstract][Full Text] [Related]
30. Potent antitumor activity of interleukin-27.
Hisada M; Kamiya S; Fujita K; Belladonna ML; Aoki T; Koyanagi Y; Mizuguchi J; Yoshimoto T
Cancer Res; 2004 Feb; 64(3):1152-6. PubMed ID: 14871851
[TBL] [Abstract][Full Text] [Related]
31. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes.
Martinotti A; Stoppacciaro A; Vagliani M; Melani C; Spreafico F; Wysocka M; Parmiani G; Trinchieri G; Colombo MP
Eur J Immunol; 1995 Jan; 25(1):137-46. PubMed ID: 7843224
[TBL] [Abstract][Full Text] [Related]
32. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection.
Dobrzanski MJ; Reome JB; Dutton RW
J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679
[TBL] [Abstract][Full Text] [Related]
33. IL-6-transfected tumor cells modulate the status of CD8(+) and CD4(+) T cells to control tumor growth.
Hsieh CL; Liu SJ; Shen CR; Chen MY; Hsu SC; Tsai JP; Li YS; Yang CJ; Chong P; Chen HW
Immunobiology; 2010 Jun; 215(6):486-91. PubMed ID: 19699006
[TBL] [Abstract][Full Text] [Related]
34. Modification of anti-tumor immunity by tolerogenic dendritic cells.
Chen L; Hasni MS; Jondal M; Yakimchuk K
Autoimmunity; 2017 Sep; 50(6):370-376. PubMed ID: 28675711
[TBL] [Abstract][Full Text] [Related]
35. IFN-gamma promotes generation of IL-10 secreting CD4+ T cells that suppress generation of CD8 responses in an antigen-experienced host.
Liu XS; Leerberg J; MacDonald K; Leggatt GR; Frazer IH
J Immunol; 2009 Jul; 183(1):51-8. PubMed ID: 19535638
[TBL] [Abstract][Full Text] [Related]
36. Knockdown of HMGB1 in tumor cells attenuates their ability to induce regulatory T cells and uncovers naturally acquired CD8 T cell-dependent antitumor immunity.
Liu Z; Falo LD; You Z
J Immunol; 2011 Jul; 187(1):118-25. PubMed ID: 21642542
[TBL] [Abstract][Full Text] [Related]
37. CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine.
Comes A; Rosso O; Orengo AM; Di Carlo E; Sorrentino C; Meazza R; Piazza T; Valzasina B; Nanni P; Colombo MP; Ferrini S
J Immunol; 2006 Feb; 176(3):1750-8. PubMed ID: 16424205
[TBL] [Abstract][Full Text] [Related]
38. STAT3-enhancing germline mutations contribute to tumor-extrinsic immune evasion.
Kogan D; Grabner A; Yanucil C; Faul C; Ulaganathan VK
J Clin Invest; 2018 May; 128(5):1867-1872. PubMed ID: 29438108
[TBL] [Abstract][Full Text] [Related]
39. Despite increased CD4+Foxp3+ cells within the infection site, BALB/c IL-4 receptor-deficient mice reveal CD4+Foxp3-negative T cells as a source of IL-10 in Leishmania major susceptibility.
Nagase H; Jones KM; Anderson CF; Noben-Trauth N
J Immunol; 2007 Aug; 179(4):2435-44. PubMed ID: 17675505
[TBL] [Abstract][Full Text] [Related]
40. Plasmacytoid dendritic cells protect against immune-mediated acute liver injury via IL-35.
Koda Y; Nakamoto N; Chu PS; Ugamura A; Mikami Y; Teratani T; Tsujikawa H; Shiba S; Taniki N; Sujino T; Miyamoto K; Suzuki T; Yamaguchi A; Morikawa R; Sato K; Sakamoto M; Yoshimoto T; Kanai T
J Clin Invest; 2019 Jul; 129(8):3201-3213. PubMed ID: 31264967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
